ASCEND:阿可替尼对比艾代拉利司联合利妥昔单抗或苯达莫司汀联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病的III期随机试验
这项全球多中心、随机、开放标签III期研究纳入310例复发或难治性慢性淋巴细胞白血病患者,按1:1随机接受阿可替尼单药或研究者选择方案(艾代拉利司联合利妥昔单抗或苯达莫司汀联合利妥昔单抗)。中位随访16.1个月,阿可替尼单药的中位无进展生存期未达到,研究者选择方案为16.5个月(HR 0.31,95%CI 0.20-0.49,P<.0001)。
要点
- 阿可替尼单药较研究者选择方案显著延长无进展生存期,风险比为0.31。
- 阿可替尼组12个月无进展生存率为88%,研究者选择方案组为68%。
- 阿可替尼组严重不良事件发生率为29%,艾代拉利司联合利妥昔单抗组为56%,苯达莫司汀联合利妥昔单抗组为26%。
核心结论
- 在复发或难治性慢性淋巴细胞白血病患者中,阿可替尼较艾代拉利司联合利妥昔单抗或苯达莫司汀联合利妥昔单抗显著改善无进展生存期,且安全性可接受。
研究设计与样本
- 全球、多中心、随机、开放标签III期研究,纳入年龄≥18岁的复发或难治性慢性淋巴细胞白血病患者,按1:1中央随机并依据del(17p)状态、东部肿瘤协作组体能状态评分和既往治疗线数分层。
- 310例患者随机分配至阿可替尼单药组(n=155)或研究者选择组(n=155;艾代拉利司联合利妥昔单抗n=119,苯达莫司汀联合利妥昔单抗n=36)。
- 患者既往接受中位2线治疗(范围1-10线)。
- 主要终点为意向治疗人群由独立审查委员会评估的无进展生存期。
主要发现
- 中位随访16.1个月(范围0.03-22.4个月),阿可替尼单药组中位无进展生存期未达到,研究者选择组为16.5个月(95%CI 14.0-17.1个月),风险比0.31(95%CI 0.20-0.49),P<.0001。
- 估计12个月无进展生存率阿可替尼组为88%(95%CI 81%-92%),研究者选择组为68%(95%CI 59%-75%)。
- 严重不良事件发生率:阿可替尼单药组29%(44/154),艾代拉利司联合利妥昔单抗组56%(66/118),苯达莫司汀联合利妥昔单抗组26%(9/35)。
- 死亡发生率:阿可替尼单药组10%(15/154),艾代拉利司联合利妥昔单抗组11%(13/118),苯达莫司汀联合利妥昔单抗组14%(5/35)。
关键数值与推荐
- 阿可替尼单药组中位无进展生存期未达到,研究者选择组为16.5个月(95%CI 14.0-17.1个月)。
- 无进展生存风险比0.31(95%CI 0.20-0.49),P<.0001。
- 12个月无进展生存率:阿可替尼组88%(95%CI 81%-92%),研究者选择组68%(95%CI 59%-75%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Acalabrutinib, a highly selective, potent, Bruton tyrosine kinase inhibitor, was evaluated in this global, multicenter, randomized, open-label, phase III study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). METHODS: Eligible patients, aged ≥ 18 years with R/R CLL, were randomly assigned 1:1 centrally and stratified by del(17p) status, Eastern Cooperative Oncology Group performance status score, and number of prior lines of therapy. Patients received acalabrutinib monotherapy or investigator's choice (idelalisib plus rituximab [I-R] or bendamustine plus rituximab [B-R]). The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC) in the intent-to-treat population. Key secondary end points included IRC-assessed overall response rate, overall survival, and safety. RESULTS: From February 21, 2017, to January 17, 2018, a total of 398 patients were assessed for eligibility; 310 patients were randomly assigned to acalabrutinib monotherapy (n = 155) or investigator's choice (n = 155; I-R, n = 119; B-R, n = 36). Patients had received a median of two prior therapies (range, 1-10). After a median follow-up of 16.1 months (range, 0.03-22.4 months), median PFS was significantly longer with acalabrutinib monotherapy (PFS not reached) compared with investigator's choice (16.5 months [95% CI, 14.0 to 17.1 months]; hazard ratio, 0.31 [95% CI, 0.20 to 0.49]; P < .0001). Estimated 12-month PFS was 88% (95% CI, 81% to 92%) for acalabrutinib and 68% (95% CI, 59% to 75%) for investigator's choice. Serious adverse events occurred in 29% of patients (n = 44 of 154) treated with acalabrutinib monotherapy, 56% (n = 66 of 118) with I-R, and 26% (n = 9 of 35) with B-R. Deaths occurred in 10% (n = 15 of 154), 11% (n = 13 of 118), and 14% (n = 5 of 35) of patients receiving acalabrutinib monotherapy, I-R, and B-R, respectively. CONCLUSION: Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.
引用
- Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020. PMID: 32459600. doi:10.1200/JCO.19.03355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。